A promising pipeline of preclinical drug candidates for leishmaniasis and chronic Chagas' disease

Manuel Saldivia, Ana Paula C A Lima, Jeremy C Mottram

Research output: Contribution to journalArticlepeer-review

Abstract

The drug discovery pipeline for leishmaniasis and trypanosomiasis has been filling with novel chemical entities with known mechanisms of action. González et al. and Braillard et al. report a cytochrome bc1 complex inhibitor as another promising preclinical candidate for visceral leishmaniasis (VL) and, in combination with benznidazole, for chronic Chagas' disease (CCD).

Original languageEnglish
Pages (from-to)211-213
Number of pages3
JournalTrends in parasitology
Volume40
Issue number3
DOIs
Publication statusPublished - 6 Mar 2024

Bibliographical note

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Keywords

  • Humans
  • Chagas Disease/drug therapy
  • Leishmaniasis/drug therapy
  • Trypanosomiasis
  • Leishmaniasis, Visceral/drug therapy
  • Trypanosoma cruzi

Cite this